Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,739,953 | $1,861,304,154 | +1% | 20.6% |
| 2. | AQR Capital Management Cliff Asness | 6,736,169 | $405,786,825 | +93% | 0.42% |
| 3. | Renaissance Technologies Jim Simons | 3,708,732 | $224,563,723 | -10% | 0.34% |
| 4. | Armistice Capital Steven Boyd | 1,671,463 | $101,207,085 | -6% | 1.52% |
| 5. | GLG Partners Noam Gottesman | 1,054,427 | $63,845,555 | +45% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | $12,887,302.92 | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | $1,062,243.06 | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | $73,176.91 | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | $6,044.11 | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | $1,805,125.51 | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.00 | 1,795 | $122,060.00 | 26,504 | 2025-06-03 | Filing | |
| $64.88 | 651 | $42,236.88 | 22,003 | 2025-06-02 | Filing | |
| $65.71 | 963 | $63,278.73 | 22,654 | 2025-05-30 | Filing | |
| $67.68 | 19,147 | $1,295,868.96 | 33,567 | 2025-03-14 | Filing | |
| $67.88 | 199 | $13,508.12 | 52,714 | 2025-03-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,997,823 | $1,210,868,182 | 0.02% | |
| 2. | 17,433,091 | $1,055,573,662 | 0.02% | |
| 3. | 14,864,328 | $900,035,060 | 0.51% | |
| 4. | 10,035,460 | $607,647,103 | 0.03% | |
| 5. | 4,207,991 | $254,008,508 | 0.02% |
News See All
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now.
8 Cheap Beginner Stocks to Buy Right Now
Talk of a slowing economy has once again gained popularity within economic circles.
Morgan Stanley Maintains Hold Rating on Incyte (INCY) Stock
On June 4, Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte Corporation (NASDAQ:INCY) with a price target of $68.00.
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025.
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript
Operator: On today's call, I am joined by Herve Hoppenot, Pablo Cagnoni, and Christiana Stamoulis, who will deliver our prepared remarks.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
12 AI Updates Worth Taking a Look At
In a Bloomberg interview, SandboxAQ CEO Jack Hidary started discussing the company's partnership with Saudi Aramco, which focuses on using AI to convert carbon emissions into valuable products.
Billionaire Hedge Funds
